New trial
Phase 1b DF6215 trial: IL-2 variant immune modulator
- Trial ID
- NCT06108479 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Location
- 21 Locations
- Published in
- New in Oncology - June 16, 2025
This open‐label study evaluates DF6215 as monotherapy and with pembrolizumab in patients with advanced solid tumors, including melanoma and ovarian cancer, to assess safety, tolerability, pharmacokinetics, and early efficacy in a first‐in‐human trial led by Dragonfly Therapeutics at U.S. and international sites.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings